Current situation of nucleosidic reverse transcriptase inhibitors

Nucleosidic reverse transcriptase inhibitors were the first class of drugs to be used for the treatment of HIV disease. Recent data on the complex pat hways allowing the virus to adapt to the drugs will lead to better manageme nt of the phenomena, Similarly, better understanding of the mechanism of th eir toxicity will allow safer use. As these drugs are simple to use, and ha ve a sustained effect over time with reasonable tolerance, nucleosidic reve rse transcriptase inhibitors are currently the main contributors to multi-d rug anti-HIV regimens. Reverse transcriptase inhibitors are currently the main contributors in mul ti-drug anti-HIV regimens.